Are checkpoints playing with fire?

Commentary on presentation by Dr Philippe Armand at BMT Tandem meeting on “Checkpoint Blockade in SCT, Data & Hope, Promise & Peril”

February 25, 2016

The Next Big Wave in Multiple Myeloma

How do we decide how to incorporate the newly approved drugs in Multiple Myeloma and what's the next wave of therapies we can expect to see evolve?

February 11, 2016

Will Unum’s approach take the CAR T cell therapy market by storm?

Unum have developed a completely different approach to traditional CAR T cell therapies. Will they make an impact in patients?

February 4, 2016

Is Ocular Toxicity a big deal with Denintuzumab Mafodotin SGN-CD19A? #JPM16

An interview with Seattle Genetics CEO, Dr Clay Siegall on CD19A ocular toxicity and the competition from checkpoint inhibitors in Hodgkin's lymphoma.

January 11, 2016

Midostaurin in AML – Better Late than Never!

An in-depth look at the FLT3 inhibitor midostaurin and its potential impact on the treatment for AML.

January 6, 2016

New Horizons in CLL Treatment

ASH 2015 interview with Dr Ian Flinn, Director of the Blood Cancer Research Program at the Sarah Cannon Research Institute.

January 5, 2016
ASH15 Late Breaker Session

New Treatments for CLL with Deletions in 17p

A look at the new CLL 17p deletion data at ASH in the late breaker session

January 4, 2016

Understanding the Cellectis UCART19 Case Report – Part 2 of an Interview with Prof Waseem Qasim

Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.

December 16, 2015

Potential of Gene Editing – Part 1 of Interview with Prof Waseem Qasim

Part 1 of an interview with Prof Waseem Qasim.

December 15, 2015

Manic Monday at ASH 2015

Commentary on "Manic Monday" at ASH 2015

December 7, 2015

Highlights from Plenary Sunday at #ASH15

Commentary on Plenary Sunday at the 2015 ASH annual meeting in Orlando.

December 6, 2015

Highlights from Saturday at ASH 2015 Annual Meeting #ASH15

Commentary on Saturday at ASH15

December 5, 2015

ASH 2015 Preview: will venetoclax fall or rise?

In the last of our American Society of Hematology (ASH) 2015 annual meeting previews, we take a broad…

December 2, 2015

ASH15 Preview on Aggressive Lymphomas

There are an encouraging number of promising therapies in development for Aggressive Lymphomas at ASH this year - which ones should you watch out for?

December 1, 2015

ASH15 Multiple Myeloma Preview

With four new approvals in multiple myeloma in 2015, ASH is expected to have a surfeit of riches to review for this disease...

November 30, 2015

ASH15 Preview Checkpoints in classical Hodgkin Lymphoma

Checkpoints in classical Hodgkins Lymphoma - how is the data holding up one year on?

November 25, 2015

Why do some FLT3 inhibitors work in AML and some don’t?

A look at the FLT3 AML landscape - what's new?

November 19, 2015

Preview of ASH15 Late Breaking Abstracts

Preview of some of the late-breaking abstracts at the 2015 annual meeting of the American Society of Hematology ASH15 in Orlando.

November 16, 2015

Strategies to overcome CAR T cell therapy resistance

Interview with a leading expert on strategies to overcome CAR T Cell Therapy Resistance

November 12, 2015

Do Cellectis CAR T Cells Really Work?

Expert opinion on First Clinical Application of TALEN Engineered Universal CAR19 T Cells in B-ALL

November 10, 2015

What IS Hot at ASH 2015 in Orlando? #ASH15 abstracts – Preview 1

Most of the abstracts for the 2015 annual meeting of the American Society of Hematology (ASH) have just gone online. This is a quick initial preview of a few that caught my attention in the immunotherapy space.

November 5, 2015